A multi-institutional study demonstrated that a blood test to detect circulating tumor DNA can accurately predict recurrence of HPV-driven oropharyngeal cancer following treatment. Results also indicated that the biomarker test may detect recurrent disease earlier than imaging or other standard methods of post-treatment surveillance.
A mutli-center observational study demonstrated the clinical validity and utility of the PROphet non-small cell lung cancer test, a plasma proteome machine learning-based decision-support tool designed to identify patient subsets benefiting from PD-1/PD-L1 inhibitor-based therapies.
